Immune Status and Disease Control of Inflammatory Airway Diseases (NCT07493629) | Clinical Trial Compass
RecruitingNot Applicable
Immune Status and Disease Control of Inflammatory Airway Diseases
China200 participantsStarted 2025-08-01
Plain-language summary
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:
1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.
Participants will:
1. Answer questions about their health and symptoms.
2. Give blood samples
3. Have lung function tests and other standard check-ups.
4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years (≥40 years for COPD patients).
✓. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.
✓. PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 \<80% predicted)
✓. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.
✓. Healthy controls: normal lung function, FeNO \<20 ppb, total IgE \<100 IU/mL, no chronic disease, smoking \<10 pack-years, no immunosuppressant use within 3 months.
Exclusion criteria
✕. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.
✕. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.
✕. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)
What they're measuring
1
Peripheral Blood Immune Cell Subset Profiling by Mass Cytometry (CyTOF)
Timeframe: baseline
2
Serum Cytokine Levels by ELISA
Timeframe: baseline
Trial details
NCT IDNCT07493629
SponsorFirst Affiliated Hospital of Ningbo University